NCT04308174View on ClinicalTrials.gov

Neoadjuvant Gemcitabine Plus Cisplatin With or Without Durvalumab in Resectable Biliary Tract Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

May 20, 2020

Primary Completion Date

June 30, 2023

Study Completion Date

December 30, 2025

Conditions
Biliary Tract NeoplasmsGallbladder CancerCholangiocarcinoma
Interventions
DRUG

Durvalumab + Gem/Cis

Neoadjuvant Durvalumab + Gemcitabine/Cisplatin

DRUG

Gem/Cis

Neoadjuvant Gemcitabine/Cisplatin

Trial Locations (1)

05505

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
collaborator

Samsung Medical Center

OTHER

lead

Asan Medical Center

OTHER

NCT04308174 - Neoadjuvant Gemcitabine Plus Cisplatin With or Without Durvalumab in Resectable Biliary Tract Cancer | Biotech Hunter | Biotech Hunter